Related Experiment Video
Updated: Mar 4, 2026
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
3.2K
New developments in the management of narcolepsy
Vivien C Abad1, Christian Guilleminault1
1Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University Outpatient Center, Redwood City, CA, USA.
Nature and Science of Sleep
|April 21, 2017
Summary
Narcolepsy, a sleep disorder linked to hypocretin neuron loss, is treated with medications like sodium oxybate and modafinil. Emerging therapies focus on hypocretin-based treatments and immunotherapy for better narcolepsy management.
Area of Science:
- Neurology
- Sleep Medicine
- Immunology
Background:
- Narcolepsy affects 0.02%-0.18% of populations in the US and Western Europe.
- Genetic factors (HLA DQB1*06-02) and potential autoimmune triggers are implicated in narcolepsy pathophysiology.
- The disorder is characterized by hypocretin signaling loss, leading to symptoms like excessive daytime somnolence (EDS) and cataplexy.
Purpose of the Study:
- To review current and emerging treatment modalities for narcolepsy.
- To discuss the underlying pathophysiology and potential autoimmune etiology of narcolepsy.
- To explore novel therapeutic strategies including hypocretin-based treatments and immunotherapy.
Main Methods:
- Review of existing literature on narcolepsy treatments.
- Analysis of genetic and pathophysiological associations.
- Examination of ongoing clinical trials for novel therapies.
Main Results:
- Current treatments like sodium oxybate, modafinil, and armodafinil manage EDS and cataplexy.
- Antidepressants serve as second-line treatments for cataplexy.
- Emerging therapies include pitolisant, GABA modulation, hypocretin peptide replacement, and immunotherapy.
Conclusions:
- Narcolepsy management involves addressing EDS, cataplexy, and other symptoms with existing and novel therapies.
- Future treatments aim to prevent hypocretin neuronal death and restore signaling.
- Research is ongoing for effective and safe treatments, including those for pediatric populations.
Keywords:
JZP-110cataplexyemerging treatmenthypocretin peptideimmunotherapynarcolepsypitolisantsodium oxybateMore Related Videos
Related Concept Videos
01:07Narcolepsy
655
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
655
01:24Sleep-Wake Cycles
3.1K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
3.1K
01:19Management of Insomnia
744
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
744
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
713
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
713
01:25Dysrhythmias VII: Nursing Management of Dysrhythmias
468
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
468
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.5K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.5K